Form 4: Janux CSO Reports Stock Sales, RSU, and Option Grants

Janux Therapeutics' Chief Scientific Officer, Thomas DiRaimondo, reported recent stock sales for tax obligations, a significant RSU grant, and new stock option awards.

Summary

• Chief Scientific Officer Thomas DiRaimondo reported transactions on January 2, 2026.
• Sold 2,505 shares of common stock at $13.73 per share to cover tax withholding obligations related to restricted stock unit vesting.
• Received a grant of 31,400 restricted stock units (RSUs), which vest in four equal annual installments starting January 1, 2027.
• Received a grant of 109,900 stock options with an exercise price of $13.65 per share.
• The stock options vest 25% on January 1, 2027, with the remainder vesting monthly over three years, and expire on January 1, 2036.
• Beneficial ownership of common stock after these transactions is 155,825 shares.
• Beneficial ownership of derivative securities (stock options) is 109,900.
• The filing also clarified previous Employee Stock Purchase Plan (ESPP) share acquisitions, noting 4,049 shares acquired on May 15, 2025, and correcting prior reporting discrepancies from January 3, 2025, regarding shares already reported on January 3, 2024, and September 27, 2024.

Sentiment

Score: 6

Explanation: The filing indicates routine executive compensation activities, including significant grants of RSUs and stock options, which are generally positive for aligning management incentives. The share sale was for tax purposes, a common occurrence, and not indicative of negative sentiment.

Positives

• Grant of 31,400 restricted stock units (RSUs) to the Chief Scientific Officer, aligning executive incentives with shareholder value.
• Grant of 109,900 stock options with an exercise price of $13.65, providing long-term incentive for management.

Negatives

• Sale of 2,505 shares of common stock, although for tax withholding, reduces direct ownership.

Future Outlook

The Chief Scientific Officer's compensation structure includes future vesting events for both restricted stock units and stock options. The 31,400 RSUs will vest in four equal annual installments beginning January 1, 2027. The 109,900 stock options will vest 25% on January 1, 2027, with the remaining balance vesting in equal monthly installments over the subsequent three-year period, and are exercisable until January 1, 2036.

Management Comments

• The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
• On January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, including the grant of restricted stock units and stock options, and a corresponding sale of shares to cover tax obligations. Such compensation structures are standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent, aligning their long-term interests with company performance.

Stakeholder Impact

• Shareholders: The grants of RSUs and stock options align the Chief Scientific Officer's long-term interests with shareholder value, potentially incentivizing performance. The tax-related sale is a minor, routine event.
• Employees: The filing mentions the Issuer's 2021 Employee Stock Purchase Plan, indicating broader employee participation in equity ownership, though the specific transactions are for an executive.

Next Steps

• Vesting of 31,400 Restricted Stock Units in four equal annual installments beginning January 1, 2027.
• Vesting of 109,900 stock options, with 25% vesting on January 1, 2027, and the remainder vesting monthly over three years.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including grants of restricted stock units and stock options, and a corresponding sale of shares to cover tax obligations. These transactions are standard practice and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

Janux Therapeutics, JANX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Beneficial Ownership, Chief Scientific Officer, Executive Compensation